Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams a...

Descripción completa

Detalles Bibliográficos
Autores principales: Haanen, John, Ernstoff, Marc, Wang, Yinghong, Menzies, Alexander, Puzanov, Igor, Grivas, Petros, Larkin, James, Peters, Solange, Thompson, John, Obeid, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295425/
https://www.ncbi.nlm.nih.gov/pubmed/32532839
http://dx.doi.org/10.1136/jitc-2020-000604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295425/
https://www.ncbi.nlm.nih.gov/pubmed/32532839
http://dx.doi.org/10.1136/jitc-2020-000604

Ejemplares similares